Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Publication date: Available online 2 March 2020Source: The Lancet HaematologyAuthor(s): Marijke Linschoten, Janine A M Kamphuis, Anna van Rhenen, Laurens P Bosman, Maarten J Cramer, Pieter A Doevendans, Arco J Teske, Folkert W Asselbergs
Source: The Lancet Haematology - Category: Hematology Source Type: research
More News: Cardiology | Cardiovascular | Heart | Hematology | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Rituxan